Ticagrelor versus Clopidogrel in the Dual Antiplatelet Regimen for Intracranial Stenting or Flow-Diverter Treatment for Unruptured Cerebral Aneurysms: A Single-Center Cohort Study

References

1. 1.↵
   1. Lin N,
   2. Cahill KS,
   3. Frerichs KU, et al

   . Treatment of ruptured and unruptured cerebral aneurysms in the USA: a paradigm shift. J Neurointerv Surg 2018;10:i69–76 doi:10.1136/jnis.2011.004978.rep pmid:30037962

   Abstract/FREE Full Text
2. 2.↵
   1. Luther E,
   2. McCarthy DJ,
   3. Brunet MC, et al

   . Treatment and diagnosis of cerebral aneurysms in the post-International Subarachnoid Aneurysm Trial (ISAT) era: trends and outcomes. J Neurointerv Surg 2020;12:682–87 doi:10.1136/neurintsurg-2019-015418 pmid:31959634

   Abstract/FREE Full Text
3. 3.↵
   1. Faught RW,
   2. Satti SR,
   3. Hurst RW, et al

   . Heterogeneous practice patterns regarding antiplatelet medications for neuroendovascular stenting in the USA: a multicenter survey. J Neurointerv Surg 2014;6:774–79 doi:10.1136/neurintsurg-2013-010954 pmid:24391160

   Abstract/FREE Full Text
4. 4.↵
   1. Gupta R,
   2. Moore JM,
   3. Griessenauer CJ, et al

   . Assessment of dual-antiplatelet regimen for Pipeline embolization device placement: a survey of major academic neurovascular centers in the United States. World Neurosurg 2016;96:285–92 doi:10.1016/j.wneu.2016.09.013 pmid:27641263

   CrossRefPubMed
5. 5.↵
   1. Gurbel PA,
   2. Bliden KP,
   3. Hiatt BL, et al

   . Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908–13 doi:10.1161/01.CIR.0000072771.11429.83

   Abstract/FREE Full Text
6. 6.↵
   1. Kuliczkowski W,
   2. Witkowski A,
   3. Polonski L, et al

   . Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2009;30:426–35 doi:10.1093/eurheartj/ehn562 pmid:19174428

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Fifi JT,
   2. Brockington C,
   3. Narang J, et al

   . Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting. AJNR Am J Neuroradiol 2013;34:716–20 doi:10.3174/ajnr.A3405 pmid:23194833

   Abstract/FREE Full Text
8. 8.↵
   1. Yang H,
   2. Li Y,
   3. Jiang Y

   . Insufficient platelet inhibition and thromboembolic complications in patients with intracranial aneurysms after stent placement. J Neurosurg 2016;125:247–53 doi:10.3171/2015.6.JNS1511 pmid:26587657

   CrossRefPubMed
9. 9.↵
   1. Asai T,
   2. Miyachi S,
   3. Izumi T, et al

   . Relationship between low response to clopidogrel and periprocedural ischemic events with coil embolization for intracranial aneurysms. J Neurointerv Surg 2016;8:752–55 doi:10.1136/neurintsurg-2015-011727 pmid:26109688

   Abstract/FREE Full Text
10. 10.↵
    1. Sedat J,
    2. Chau Y,
    3. Gaudart J, et al

    . Prasugrel versus clopidogrel in stent-assisted coil embolization of unruptured intracranial aneurysms. Interv Neuroradiol 2017;23:52–59 doi:10.1177/1591019916669090 pmid:27760885

    CrossRefPubMed
11. 11.↵
    1. Cho WS,
    2. Lee J,
    3. Ha EJ, et al

    . Low-dose prasugrel vs clopidogrel-based tailored premedication for endovascular treatment of cerebral aneurysms. Neurosurgery 2019;85:E52–59 doi:10.1093/neuros/nyy341 pmid:30137613

    CrossRefPubMed
12. 12.↵
    FDA approves blood-thinning drug Brilinta to treat acute coronary syndromes. https://wayback.archive-it.org/7993/20170112024017/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm263964.htm. Accessed July 20, 2011
13. 13.↵
    1. Wallentin L,
    2. Becker RC,
    3. Budaj A, et al

    . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–57 doi:10.1056/NEJMoa0904327 pmid:19717846

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Bonaca MP,
    2. Bhatt DL,
    3. Cohen M, et al

    . Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791–800 doi:10.1056/NEJMoa1500857 pmid:25773268

    CrossRefPubMed
15. 15.↵
    1. Johnston SC,
    2. Amarenco P,
    3. Albers GW, et al

    . Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 2016;375:35–43 doi:10.1056/NEJMoa1603060 pmid:27160892

    CrossRefPubMed
16. 16.↵
    1. Easton JD,
    2. Aunes M,
    3. Albers GW, et al

    . SOCRATES Steering Committee and Investigators. Risk for major bleeding in patients receiving ticagrelor compared with aspirin after transient ischemic attack or acute ischemic stroke in the SOCRATES study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). Circulation 2017;136:907–16 doi:10.1161/CIRCULATIONAHA.117.028566 pmid:28655834

    Abstract/FREE Full Text
17. 17.↵
    1. Wang Y,
    2. Minematsu K,
    3. Wong KS, et al

    . Ticagrelor in acute stroke or transient ischemic attack in Asian patients: from the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). Stroke 2017;48:167–73 doi:10.1161/STROKEAHA.116.014891

    Abstract/FREE Full Text
18. 18.↵
    1. Amarenco P,
    2. Albers GW,
    3. Denison H, et al

    . Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol 2017;16:301–10 doi:10.1016/S1474-4422(17)30038-8 pmid:28238711

    CrossRefPubMed
19. 19.↵
    1. Orru E,
    2. Rice H,
    3. De Villiers L, et al

    . First clinical experience with the new Surpass Evolve flow diverter: technical and clinical considerations. J Neurointerv Surg 2020;12:974–80 doi:10.1136/neurintsurg-2019-015734 pmid:32051324

    Abstract/FREE Full Text
20. 20.↵
    1. Agid R,
    2. Willinsky RA,
    3. Lee SK, et al

    . Characterization of aneurysm remnants after endovascular treatment: contrast-enhanced MR angiography versus catheter digital subtraction angiography. AJNR Am J Neuroradiol 2008;29:1570–74 doi:10.3174/ajnr.A1124 pmid:18499789

    Abstract/FREE Full Text
21. 21.↵
    1. Agid R,
    2. Schaaf M,
    3. Farb R

    . CE-MRA for follow-up of aneurysms post stent-assisted coiling. Interv Neuroradiol 2012;18:275–83 doi:10.1177/159101991201800305 pmid:22958765

    CrossRefPubMed
22. 22.↵
    1. Roy D,
    2. Milot G,
    3. Raymond J

    . Endovascular treatment of unruptured aneurysms. Stroke 2001;32:1998–2004 doi:10.1161/hs0901.095600 pmid:11546888

    Abstract/FREE Full Text
23. 23.↵
    1. Taylor LI,
    2. Dickerson JC,
    3. Dambrino RJ, et al

    . Platelet testing in flow diversion: a review of the evidence. Neurosurg Focus 2017;42:E5 doi:10.3171/2017.3.FOCUS1746 pmid:28565991

    CrossRefPubMed
24. 24.↵
    1. Kim KS,
    2. Fraser JF,
    3. Grupke S, et al

    . Management of antiplatelet therapy in patients undergoing neuroendovascular procedures. J Neurosurg 2018;129:890–905 doi:10.3171/2017.5.JNS162307 pmid:29192856

    CrossRefPubMed
25. 25.↵
    1. Kim CH,
    2. Hwang G,
    3. Kwon OK, et al

    . P2Y12 reaction units threshold for implementing modified antiplatelet preparation in coil embolization of unruptured aneurysms: a prospective validation study. Radiology 2017;282:542–51 doi:10.1148/radiol.2016160542 pmid:27603789

    CrossRefPubMed
26. 26.↵
    1. Delgado Almandoz JE,
    2. Crandall BM,
    3. Scholz JM, et al

    . Last-recorded P2Y12 reaction units value is strongly associated with thromboembolic and hemorrhagic complications occurring up to 6 months after treatment in patients with cerebral aneurysms treated with the Pipeline Embolization Device. AJNR Am J Neuroradiol 2014;35:128–35 doi:10.3174/ajnr.A3621 pmid:23828107

    Abstract/FREE Full Text
27. 27.↵
    1. Price MJ,
    2. Berger PB,
    3. Teirstein PS, et al

    . Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097–105 doi:10.1001/jama.2011.290

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Gurbel PA,
    2. Bliden KP,
    3. Butler K, et al

    . Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120:2577–85 doi:10.1161/CIRCULATIONAHA.109.912550

    Abstract/FREE Full Text
29. 29.↵
    1. Orme RC,
    2. Parker WA,
    3. Thomas MR, et al

    . Study of two dose regimens of ticagrelor compared with clopidogrel in patients undergoing percutaneous coronary intervention for stable coronary artery disease (STEEL-PCI). Circulation 2018;138:1290–1300 doi:10.1161/CIRCULATIONAHA.118.034790 pmid:29930021

    CrossRefPubMed
30. 30.↵
    1. Gurbel PA,
    2. Bliden KP,
    3. Butler K, et al

    . Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010;121:1188–99 doi:10.1161/CIRCULATIONAHA.109.919456

    Abstract/FREE Full Text
31. 31.↵
    1. Hanel RA,
    2. Taussky P,
    3. Dixon T, et al

    . Safety and efficacy of ticagrelor for neuroendovascular procedures: a single center initial experience. J Neurointerv Surg 2014;6:320–02 doi:10.1136/neurintsurg-2013-010699 pmid:23771209

    Abstract/FREE Full Text
32. 32.↵
    1. Moore JM,
    2. Adeeb N,
    3. Shallwani H, et al

    . A multicenter cohort comparison study of the safety, efficacy, and cost of ticagrelor compared to clopidogrel in aneurysm flow diverter procedures. Neurosurgery 2017;81:665–71 doi:10.1093/neuros/nyx079 pmid:28475757

    CrossRefPubMed
33. 33.↵
    1. Soize S,
    2. Foussier C,
    3. Manceau PF, et al

    . Comparison of two preventive dual antiplatelet regimens for unruptured intracranial aneurysm embolization with flow diverter/disrupter: a matched-cohort study comparing clopidogrel with ticagrelor. J Neuroradiol 2019;46:378–83 doi:10.1016/j.neurad.2019.01.094 pmid:30731144

    CrossRefPubMed
34. 34.↵
    1. Narata AP,
    2. Amelot A,
    3. Bibi R, et al

    . Dual antiplatelet therapy combining aspirin and ticagrelor for intracranial stenting procedures: a retrospective single center study of 154 consecutive patients with unruptured aneurysms. Neurosurgery 2019;84:77–83 doi:10.1093/neuros/nyy002 pmid:29490066

    CrossRefPubMed
35. 35.↵
    1. Benjamin EJ,
    2. Blaha MJ,
    3. Chiuve SE, et al

    . American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 2017;135:e146-603 doi:10.1161/CIR.0000000000000485 pmid:28122885

    CrossRefPubMed
36. 36.↵
    1. Bhatia KD,
    2. Kortman H,
    3. Orru E, et al

    . Periprocedural complications of second-generation flow diverter treatment using Pipeline Flex for unruptured intracranial aneurysms: a systematic review and meta-analysis. J Neurointerv Surg 2019;11:817–24 doi:10.1136/neurintsurg-2019-014937 pmid:31147438

    Abstract/FREE Full Text
37. 37.↵
    1. Phan K,
    2. Huo YR,
    3. Jia F, et al

    . Meta-analysis of stent-assisted coiling versus coiling-only for the treatment of intracranial aneurysms. J Clin Neurosci 2016;31:15–22 doi:10.1016/j.jocn.2016.01.035 pmid:27344091

    CrossRefPubMed
38. 38.↵
    1. Brinjikji W,
    2. Murad MH,
    3. Lanzino G, et al

    . Endovascular treatment of intracranial aneurysms with flow diverters: a meta-analysis. Stroke 2013;44:442–47 doi:10.1161/STROKEAHA.112.678151

    Abstract/FREE Full Text
39. 39.↵
    1. Podlasek A,
    2. Al Sultan AA,
    3. Assis Z, et al

    . Outcome of intracranial flow diversion according to the antiplatelet regimen used: a systematic review and meta-analysis. J Neurointerv Surg 2020;12:148–55 doi:10.1136/neurintsurg-2019-014996 pmid:31273075

    Abstract/FREE Full Text
40. 40.↵
    1. Kabbasch C,
    2. Goertz L,
    3. Siebert E, et al

    . WEB embolization versus stent-assisted coiling: comparison of complication rates and angiographic outcomes. J Neurointerv Surg 2019;11:812–16 doi:10.1136/neurintsurg-2018-014555 pmid:30674636

    Abstract/FREE Full Text
41. 41.↵
    1. Skukalek SL,
    2. Winkler AM,
    3. Kang J, et al

    . Effect of antiplatelet therapy and platelet function testing on hemorrhagic and thrombotic complications in patients with cerebral aneurysms treated with the Pipeline Embolization Device: a review and meta-analysis. J Neurointerv Surg 2016;8:58–65 doi:10.1136/neurintsurg-2014-011145 pmid:25385746

    Abstract/FREE Full Text